University of Virginia Cancer Centre researchers (USA) have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment. Doctors may be able to use the findings to overcome this treatment failure and save the lives of thousands of women every year. The discovery, from the lab of ..read more

Pharma and GmbH announced today that the UK’s National Institute of Health and Care Excellence (NICE) published on February 19 the Final Draft Guidance recommending the use of rucaparib in England, Wales, and Northern Ireland as an option for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. This is ..read more

A new report highlights the overwhelming economic and societal cost of ovarian cancer in Australia. Ovarian Cancer Australia (OCA) today highlights new figures revealing the A$3.8 billion annual impact of ovarian cancer on the Australian economy. This data, part of the Socioeconomic Burden Study led by the World Ovarian Cancer Coalition (WOCC), shows that 90 ..read more

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumours, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer, and lung adenocarcinoma. However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field. Recently, Insilico Medicine (“Insilico”) announced that the team, with the support of its ..read more

A mathematical modeling study conducted in Germany suggests that ovarian cancer incidence could be reduced and healthcare savings boosted if women who have already completed their families were offered fallopian tube removal during any other suitable abdominal surgeries. Angela Kather and Ingo Runnebaum of Jena University Hospital, Germany, and colleagues present these findings on January ..read more

It’s a little pill with big responsibilities. But despite its primary role to prevent pregnancy, the contraceptive pill (or ‘the Pill’) could also help reduce the risk of ovarian cancer, according to new research from the University of South Australia. Screening for risk factors of ovarian cancer using artificial intelligence, UniSA researchers found that the oral contraceptive pill reduced ..read more

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy. This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed ..read more

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumours use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The work, published in Nature, points toward a promising new immunotherapy approach for ovarian cancer, which is notoriously aggressive and hard to treat. A significant obstacle in treating ovarian ..read more

Most uterine cancers have excellent five-year survival rates – up to 95% for localised cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer. Now, researchers at MUSC Hollings Cancer Centre say that in the course of developing a new model for ovarian cancer ..read more

In this study, the Cancer Research UK-funded scientists will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids. If this research is successful, work ..read more